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Abstract: microRNAs (miRNAs) cause mRNA degradation or translation suppression of 
their target genes. Previous studies have found direct involvement of miRNAs in cancer 
initiation and progression. Artificial miRNAs, designed to target single or multiple genes 
of  interest,  provide  a  new  therapeutic  strategy  for  cancer.  This  study  investigates  the  
anti-tumor effect of a novel artificial miRNA, miR P-27-5p, on breast cancer. In this study, 
we reveal  that miR P-27-5p downregulates  the  differential  gene expressions  associated 
with  the  protein  modification  process  and  regulation  of  cell  cycle  in  T-47D  cells. 
Introduction of this novel artificial miRNA, miR P-27-5p, into breast cell lines inhibits cell 
proliferation and induces the first ―gap‖ phase (G1) cell cycle arrest in cancer cell lines but 
does  not  affect  normal  breast  cells.  We  further  show  that  miR  P-27-5p  targets  the  
3′-untranslated mRNA region (3′-UTR) of cyclin-dependent kinase 4 (CDK4) and reduces 
both the mRNA and protein level of CDK4, which in turn, interferes with phosphorylation 
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of the  retinoblastoma protein (RB1).  Overall, our data suggest  that the effects  of miR  
p-27-5p on cell proliferation and G1 cell cycle arrest are through the downregulation of 
CDK4 and the suppression of RB1 phosphorylation. This study opens avenues for future 
therapies targeting breast cancer.  
Keywords: miR P-27-5p; exon array; cyclin-dependent kinase 4; cell cycle; breast cancer; 
retinoblastoma protein 
 
1. Introduction 
microRNAs (miRNAs) cause mRNA degradation or translation suppression of their target genes. 
Previous studies have shown that miRNAs play crucial roles in tumorigenesis by targeting the mRNAs 
of oncogenes or tumor suppressors [1,2]. Many reports indicate that miRNA expression is altered in 
tumor tissues, suggesting that these miRNAs could be potential markers for detection and prognosis in 
human cancers [3,4]. Because of the critical role of miRNAs as regulators of cell fate, analyzing and 
manipulating miRNAs within cancer cells may provide powerful avenues for diagnosis, prognosis, 
drug discovery, and therapeutics [5]. miRNA P-27-5p (miR P-27-5p) is a novel miRNA we recently 
discovered in  breast  cancer cells  [6]. In this  study, we investigate why this  artificial miRNA can 
suppress breast cancer cell growth. 
Microarray  is  a  powerful  high-throughput  technique  for  determining  changes  in  global  gene 
expressions in functional genomics [7,8]. It can measure expression of tens of thousands of discrete 
sequences in a single array [9]. The exon array is useful for exon-level expression profiling at the 
whole-genome scale on a single array [10]. The oligonucleotide probes of exon arrays greatly differ 
from those of conventional 3′ expression arrays in their design, density, and coverage. This technique 
has been used for novel genes discoveries [11], gene function determination, drug evaluation, pathway 
dissection, and clinical sample classification [9,12]. 
The G1/S cell cycle checkpoint controls the passage of eukaryotic cells from G1 into the DNA 
synthesis phase (S). Two cell cycle kinases, cyclin-dependent kinase 4/6 (CDK4/6)-cyclin D [13–15] 
and CDK2-cyclin E [16], and the transcription complex that includes retinoblastoma protein (RB1) and 
E2F are essential in controlling this checkpoint [17]. CDK4, a member of the Ser/Thr protein kinase 
family, binds cyclin D and subsequently phosphorylates RB1, leading to cell cycle regulation, which is 
thought to occur through hyperphosphorylation-induced release of the E2F transcription factors from 
the large pocket [17]. A breakdown in the regulation of this cycle can lead to out-of-control growth 
and contribute to tumor formation. Recently, many inhibitors specifically targeted to CDK4 have been 
developed for the treatment of breast cancer [14,15]. 
In this study, we show that miR P-27-5p inhibits the growth of breast cancer cells and induces cell 
cycle arrest at the G1 phase. Exon array, Western blot, real-time polymerase chain reaction (PCR), and 
luciferase report analyses have revealed that miR P-27-5p targets CDK4. Our observations indicate 
that miR P-27-5p inhibits cancer cell proliferation and triggers G1 cell cycle arrest by targeting CDK4 
and suppressing phosphorylation of RB1. Int. J. Mol. Sci. 2012, 13  6354 
 
 
2. Results and Discussion 
2.1. miR P-27-5p Downregulates Gene Expressions Associated with Cell Growth, Cell Cycle, and 
Phosphorylation in T-47D Cells 
In addition to translation suppression, miRNAs cause mRNA degradation of their target genes;  
the  changes  at  the  mRNA  level  can  be  detected  by  microarray  experiments  [18,19].  We  used  a  
high-throughput exon array to identify the miR P-27-5p–regulated genes and potential targets. The 
results of exon array data have been submitted to the GEO database, and the series record is GSE28657. 
To screen and investigate the gene expression profile and possible biological functions of miR  
P-27-5p regulation in breast cancer T-47D cells, we used our previously developed approach [20,21]. 
There were 2590 genes with a significant downregulated change in expression level between control 
and miR P-27-5p–transfected T-47D cells (Supporting Information Table S.1). These downregulated 
expressed  genes  were  used  to  construct  the  protein-protein  interaction  (PPI)  network.  The  human 
protein interaction network (PIN) was downloaded from the Human Protein Reference Database [22], 
and only the largest connected component was studied. The differentially downregulated expressed 
proteins in the miR P-27-5p–related network was further predicted by functional enrichment analysis. 
Among the PPI networks, we found that CDK4 and RB1 were involved in the network and the RB1 
interacted with 19 proteins including CDK4 (Figure 1A). 
Figure 1. A protein-protein interaction network and the biological functions regulated by 
miR P-27-5p in T-47D cells. Gene expression profiles were determined using exon arrays. 
(A)  The  significantly  differentially  expressed  proteins  in  miR  P-27-5p–overexpressing 
tumor cells were used to construct the protein-protein interaction (PPI) network; (B) All 
proteins in the network were further analyzed for clustering of functional profiles by using 
BiNGO. It uncovered key functional relationships, particularly cell proliferation and cycle 
and phosphorylation. 
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Figure 1. Cont. 
 
All proteins in the network were further analyzed for clustering of functional profiles using BiNGO 
(p < 0.001). BiNGO [23,24], a Cytoscape [24] plug-in, was used to determine which Gene Ontology 
(GO)  terms  were  significantly  overrepresented  (the  hypergeometric  test,  Benjamini  and  Hochberg 
False  Discovery  Rate  correction,  p  ≤  0.001)  in  miR  P-27-5p–related  networks.  Key  functional 
relationships  were  revealed,  including  the  protein  modification  process,  protein  amino  acid 
phosphorylation,  phosphorylation,  regulation  of  cell  proliferation,  posttranslational  protein 
modification, the cellular protein metabolic process, positive regulation of cellular process, interphase, 
and regulation of cell cycle (Figure 1B and Table 1). 
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Table 1. The functions and genes regulated by miR P-27-5p. 
Description  Gene List   p-Value  Adj. p-Value 
protein modification 
process 
(GO:0006464) 
STK36 STYX USE1 EIF5A CASK RPS6KB2 AURKB MAP3K6 MAP3K5 ERO1LB ST3GAL3 TRAK1 IFNG CLK4 
LOX INSR SYK EGFR DBNL BCR TNIK PTPRF DTL WNK1 PTPRS PIM2 HDAC11 SUV420H2 PPP1CA 
HUWE1  MAPK3  AMFR  UBA52  TNFAIP1  GGCX  FGFR4  ERBB3  STK11  ERBB2  MAPKAPK3  NEDD8 
ANAPC11  EPHB3  ACP1  SRC  EPHB6  UBE2D2  PTK6  PRKRA  GNMT  TRAF7  MGAT4B  B4GALT1  P4HB 
MAP2K2 TKT HDAC5 CDC42BPG HDAC3 PLK1 DOHH GRK6 SPTBN1 EAF2 MERTK HDAC6 BCKDK 
FASTK UCHL1 CAD AKT1 PAK7 PIGM PRMT2 ASH2L HSF1 PAK4 TGFA RAB6A KLHL20 CTBP1 PIGX 
DDB1 PIGU PIGT CDK6 UBE2I CDK4 PRKCE CDK2 SRPK1 G6PD BTG1 DDB2 DHPS SERP1 PRKCZ 
PPP4R2  RAB3D  UBE3A  USP5  GPAA1  ABI2  STUB1  IGF1R  STT3A  CDC2L2  PER1  C19ORF62  PRKAA2 
PPP3CA THBS1 YES1 QSOX1 KAT2A PDK2 LRSAM1 FLT1 FLT4 SIRT2 RPS6KA1 MAPK13 CSNK1E RSRC1 
MAPK15 ARAF JAK1 DPM2 DPM3 IRF4 RBM14 RNF40 
7.98 ×  10
−8  6.34 ×  10
−6 
protein amino acid 
phosphorylation 
(GO:0006468) 
BCKDK FASTK STK36 CASK RPS6KB2 CAD AURKB AKT1 PAK7 MAP3K6 MAP3K5 HSF1 PAK4 IFNG CLK4 
TGFA INSR SYK EGFR DBNL CTBP1 BCR TNIK WNK1 CDK6 PIM2 CDK4 PRKCE CDK2 SRPK1 MAPK3 
PRKCZ FGFR4 ERBB3 STK11 ERBB2 MAPKAPK3 ABI2 EPHB3 SRC IGF1R EPHB6 CDC2L2 PTK6 PRKRA 
PRKAA2  THBS1  YES1  PDK2  FLT1  MAP2K2  FLT4  TKT  CDC42BPG  RPS6KA1  MAPK13  CSNK1E  PLK1 
RSRC1 MAPK15 ARAF GRK6 JAK1 SPTBN1 MERTK 
3.24 ×  10
−6  1.43 ×  10
−4 
phosphorylation 
(GO:0016310) 
BCKDK UQCRC1 FASTK STK36 SNCA CASK RPS6KB2 CAD AURKB AKT1 PAK7 MAP3K6 MAP3K5 HSF1 
PAK4 IFNG CLK4 TGFA INSR SYK EGFR DBNL CTBP1 BCR TNIK WNK1 CDK6 PIM2 CDK4 PRKCE CDK2 
SRPK1  ATP6V1A  MAPK3  PRKCZ  FGFR4  NDUFB8  ERBB3  STK11  ERBB2  MAPKAPK3  ABI2  ATP6V1B1 
EPHB3 SRC IGF1R EPHB6 CDC2L2 PTK6 PRKRA PRKAA2 THBS1 YES1 PDK2 ATP5J2 FLT1 MAP2K2 
FLT4  TKT  CDC42BPG  RPS6KA1  MAPK13  PLK1  CSNK1E  RSRC1  MAPK15  ARAF  GRK6  JAK1  SPTBN1 
MERTK 
2.66 ×  10
−5  9.24 ×  10
−4 
regulation of cell 
proliferation 
(GO:0042127) 
FGF18 EIF5A GJA1 STRN SSR1 MEN1 MAGED1 PGR BNIPL CDKN2A ASH2L HSF1 APOE CDKN2D HEY2 
IFNG TGFA RARB DLG5 ODZ1 NR2F2 INSR LTA SYK EGFR CTBP1 CAPNS1 PTPRF DTL RXFP2 HTR4 
ESR1 CDK6 ESR2 RB1 CDK4 RPS4X CDK2 RBBP9 MXD4 NME2 BTG1 NME1 DHPS ATPIF1 SMARCA2 
CAV2 PRKCZ DERL2 FGFR4 MVD TBC1D8 ERBB3 STK11 FOXM1 ERBB2 BCL2L1 MIF IGF1R PRKRA 
ADRA2A RNF10 BCL6 THBS1 TINF2 EMD B4GALT1 FLT1 NF2 CREB3 TAF6 FLT4 CSNK2B TKT FZD7 
CAPN1 TSC2 GLMN PBX1 ADRA1D IGFBP5 
8.40 ×  10
−7  4.35 ×  10
−5 Int. J. Mol. Sci. 2012, 13  6357 
 
 
Table 1. Cont. 
Description  Gene List  p-Value  Adj. p-Value 
post-translational 
protein modification 
(GO:0043687) 
STK36 STYX USE1 CASK RPS6KB2 AURKB MAP3K6 MAP3K5 ERO1LB IFNG CLK4 INSR SYK EGFR DBNL 
BCR TNIK PTPRF DTL WNK1 PTPRS HDAC11 PIM2 SUV420H2 PPP1CA HUWE1 MAPK3 AMFR TNFAIP1 
GGCX FGFR4 ERBB3 STK11 ERBB2 MAPKAPK3 NEDD8 ANAPC11 EPHB3 ACP1 SRC EPHB6 UBE2D2 
PTK6 PRKRA TRAF7 MAP2K2 TKT HDAC5 CDC42BPG HDAC3 PLK1 GRK6 SPTBN1 EAF2 MERTK HDAC6 
BCKDK FASTK UCHL1 CAD AKT1 PAK7 PRMT2 HSF1 ASH2L PAK4 TGFA RAB6A KLHL20 CTBP1 DDB1 
PIGU PIGT UBE2I CDK6 PRKCE CDK4 SRPK1 CDK2 BTG1 DDB2 PRKCZ RAB3D UBE3A USP5 GPAA1 
ABI2 STUB1 IGF1R CDC2L2 C19ORF62 PRKAA2 PPP3CA THBS1 YES1 QSOX1 KAT2A PDK2 LRSAM1 FLT1 
FLT4 SIRT2 RPS6KA1 MAPK13 CSNK1E RSRC1 MAPK15 ARAF JAK1 IRF4 RBM14 RNF40 
2.96 ×  10
−7  1.96 ×  10
−5 
cellular protein 
metabolic process 
(GO:0044267) 
USE1 RPLP2 AURKB  CCT3  MAP3K6  MAP3K5 ERO1LB  RPLP0 RPLP1  IFNG CLK4 TRAK1 FAU  RPL10 
PSENEN SYK DBNL BCR TNIK PTPRF WNK1 PTPRS PIM2 SUV420H2 PPP1CA RPS19 HUWE1 BACE2 
BACE1 MAPK3 AMFR GGCX ERBB3 RAD23A ERBB2 EPHB3 ACP1 EPHB6 RPS28 MGAT4B RPSA MAP2K2 
TKT RPS6 RPS7 CCT7 CDC42BPG RPL18A GRK6 BCKDK NARS FASTK QARS CANX HSF1 ASH2L TGFA 
RAB6A  CTBP1  SRPK1  G6PD  EEF1G  EEF1D  SERP1  TUFM  RAB3D  USP5  GPAA1  ABI2  RPL36  STT3A 
MRPL12 PER1 C19ORF62 PRKAA2 PPP3CA THBS1 QSOX1 PDK2 LRSAM1 EIF2B1 RPL28 RPL29 RPS6KA1 
CSNK1E RPL22 PSMD11 MAPK13 ARAF MAPK15 DPM2 DPM3 RBM14 STK36 STYX EIF5A CASK RPS6KB2 
ST3GAL3 LOX INSR RPS27A EGFR DTL EEF2 HDAC11 UBA52 TNFAIP1 FGFR4 DERL2 EEF1B2 STK11 
MAPKAPK3  NEDD8  ANAPC11  DERL3  SRC  EIF3D  UBE2D2  PSMB6  EIF3H  RPL6  PTK6  PSMB3  EIF3F 
PRKRA RPL8 EIF3K EIF3L GNMT TRAF7 B4GALT1 P4HB EEF1A1 SEC11A EIF4B HDAC5 ATF6 HDAC3 
PPIA DOHH PLK1 PSMC3 SPTBN1 DNAJB1 EAF2 MERTK HDAC6 COPA UCHL1 CAD AKT1 PAK7 PRMT2 
PIGM PAK4 PSMD2 KLHL20 PIGX DDB1 PIGU PIGT UBE2I CDK6 PRKCE RPS4X CDK4 CDK2 BTG1 
TBCD DDB2 DHPS PRKCZ PPP4R2 FKBP8 APH1A UBE3A FKBP4 APH1B STUB1 IGF1R CDC2L2 LARS 
YES1 KAT2A FLT1 FLT4 SIRT2 NCSTN RPL13A RSRC1 JAK1 IRF4 RNF40 
4.47 ×  10
−13  1.78 ×  10
−10 Int. J. Mol. Sci. 2012, 13  6358 
 
 
Table 1. Cont. 
Description  Gene List  p-Value  Adj. p-Value 
positive regulation of 
cellular process 
(GO:0048522)  
MMS19 XRCC5 FGF18 THRA SNCA UTRN RPS6KB2 CASK EIF5A ITSN1 SSR1 MAGED1 PGR MAP3K5 
CDKN2A  HTRA2  CD44  PACSIN3  APOE  IFNG  PSENEN  RARB  INSR  SYK  EGFR  PLD2  CAPNS1  PTPRF 
PCBD1 DFFA DTL HTR4 MED12 PIM2 TBR1 NCAM1 SPAG9 NME2 RPS19 NME3 PIAS3 NME1 VAMP3 
SMARCA2 SMARCA4 CAV2 DERL2 FGFR4 MVD ERBB3 PFKFB2 GLUD1 ERBB2 RRM2B ANAPC11 BCL2L1 
TUBB PSMB6 ARPC2 SMARCB1 PSMB3 P2RY2 NUMB PRKRA ADRA2A RNF10 TRAF7 TRAF4 B4GALT1 
DVL2 TP53BP1 TEAD1 TKT TPD52L1 RPS6 SREBF2 ATF6 TRAF3IP2 HDAC5 ATF4 PSMC3 PLK1 IKBKG 
GLMN RFX3 PDZK1 PDCD6 ADRA1D PC HDAC6 E2F1 RTN4 LZTS2 FASTK GJA1 PPOX RFXANK MEN1 
AKT1 BNIPL FOS CCNE1 ASH2L MAPT HEY2 PSMD2 TGFA RHOC NR2F2 CASP2 LTA ZFP36 RXFP2 ESR1 
CDK6 ESR2 RB1 PFKM CDK4 RPS4X PRKCE HMGA1 CDK2 FLNA PRPF6 SCAP NCOA3 BTG1 IGF2R 
SORT1 DHPS EEF1D C6ORF108 BID MBL2 PRKCZ APH1A TBC1D8 UBE3A USP5 FOXM1 APH1B TRAIP 
STUB1 CALCOCO1 MIF IGF1R MRPL12 SOS2 C19ORF62 BCL6 THBS1 TINF2 TERF1 PHLDA1 FLT1 NF2 
CREB3 PSAP FLT4 MAP1B BIRC5 DPYSL2 FZD7 CAPN1 NCSTN PKNOX1 PSMD11 CSNK1E MAPK15 BRE 
PBX1 IRF4 RBM14 DNM2 
1.41 ×  10
−10  2.52 ×  10
−8 
interphase 
(GO:0051325) 
E2F1 EGFR TPD52L1 BIRC5 CDK6 ZNF655 RB1 CDK4 RPS6 CDK2 AKT1 CCNE1 SIN3A CDKN2A CDKN2D 
PPP3CA TERF1 DNM2 
1.90 ×  10
−5  6.87 ×  10
−4 
regulation of cell 
cycle 
(GO:0051726) 
E2F1 E2F2 CDT1 MEN1 AKT1 GSS CDKN2A CLP1 CDKN2D IFNG TGFA FANCG NR2F2 INSR EGFR BCR 
DTL DDB1 CDK6 RB1 TACC3 CDK4 CDK2 RAD1 CHMP1A SGSM3 PRNP MAD2L2 DST SMARCA4 CAV2 
STK11  FOXM1  ZNF655  CDC37  MIF  BCL6  C19ORF62  THBS1  TERF1  TAF6  CREB3  BIRC5  RPS6  SIRT2 
HDAC3 PLK1 TSC2 CKS2 BRE DGKZ 
6.92 ×  10
−7  3.82 ×  10
−5 Int. J. Mol. Sci. 2012, 13  6359 
 
2.2. miR P-27-5p Overexpression Inhibits the Growth of Breast Cancer Cells 
From exon array data, network and functional enrichment analysis, we found that miR P-27-5p 
overexpression  could  downregulate  the  gene  expression  levels  involved  in  cell  proliferation.  To 
evaluate  the  effect  of  miR  P-27-5p  on  cell  growth,  a  methylthiazoletetrazolium  (MTT)  cell 
proliferation assay was used as described above. MCF-10A, MCF-7 and T-47D were transfected with 
miR P-27-5p mimics or negative control (NC). MTT assays were performed at 24 h, 48 h, and 72 h. As 
shown in Figure 2, transfection of miR P-27-5p into cell lines significantly inhibited cell proliferation 
of breast cancer cells MCF-7 and T-47D, but not the normal cells MCF-10A. Additionally, we found 
that transfection of antisense miR P-27-5p into cancer cells promoted cell proliferation (Figure 3). 
These results indicate that miR P-27-5p has an adverse effect on breast cancer cell proliferation. 
Figure 2. Inhibitory effect of miR P-27-5p on cell proliferation. The breast normal cells 
MCF-10A (A) and cancer cells MCF-7 (B) and T-47D (C) were transfected with 60 nM 
miR P-27-5p (red bar) and NC mimetics (blue bar). Cell viability was determined using an 
MTT assay. The relative cell proliferation was examined at the indicated time points by 
MTT. The absorbance of MTT by each sample was recorded at 570 nm after staining. The 
error bar shows SE for three independent experiments. 
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Figure 3. The effect of downregulation of miR P-27-5p on cell proliferation. The breast 
normal cells MCF-10A (A) and cancer cells MCF-7 (B) and T-47D (C) were transfected 
with 60 nM antisense miR P-27-5p (purple bar) and NC (green bar), respectively. Cell 
viability was determined using an MTT assay. The relative cell proliferation was examined 
at the indicated time points by methylthiazoletetrazolium (MTT). The absorbance of MTT 
by each sample was recorded at 570 nm after staining. The error bar shows SE for three 
independent experiments. 
 
2.3. miR P-27-5p Induces G1 Arrest in Breast Cancer Cells 
In addition to cell proliferation, miR P-27-5p downregulates the genes involved in the cell cycle.  
To investigate the effect of miR P-27-5p on cell cycle progression of breast normal/cancer cells, their 
DNA contents were analyzed by flow cytometry, and the derived data were used to investigate the 
phase distribution of the cell cycle. Cells with 2 n and 4 n DNA content correspond to the G0/G1 and Int. J. Mol. Sci. 2012, 13  6361 
 
 
G2/M phases, respectively. Cells with a DNA content between 2 n and 4 n correspond to the S phase. 
As shown in Figure 4, after transfection with miR P-27-5p, the DNA percentage of the G0/G1 phase 
was increased from 65.41% to 73.96% in MCF-7 cells and from 64.87% to 83.27% in T-47D cells, but 
no significant change in MCF-10A cells was noted. These results show that miR P-27-5p induces G1 
cell cycle arrest in breast cancer cells but not in normal cells. 
Figure 4. G0/G1 arrest by miR P-27-5p. The breast normal cells (MCF-10A) (A), and 
cancer  cells  MCF-7  (B)  and  T-47D  (C)  were  transfected  with  miR  P-27-5p  and  NC 
mimetics (100 nM) for 48 h. Then, cell cycle distributions of these cells were analyzed by 
flow cytometry. 2N: cells with diploid DNA content; and 4N: cells with tetraploid DNA 
content. The experiments were performed in triplicates. 
 
 
2.4. Down-Regulation of CDK4 by miR P-27-5p at mRNA and Protein Levels via Direct  
Targeting 3′-UTR 
From exon array and network analysis, we found CDK4 is important in miR P-27-5p–regulated 
function. We used the sequence alignment method to examine whether CDK4 is a potential target of 
miR P-27-5p. Figure 5A shows that the sequence of miR P-27-5p is complimentary to the 3′-UTR 
region of CDK4. To investigate whether miR P-27-5p directly recognizes the 3′-UTR of CDK4, we 
cloned the fragment containing the presumed target site into 3′-UTR of the luciferase gene. Figure 5B 
shows  that  transfection  with  miR  P-27-5p  resulted  in  a  significant  decrease  in  luciferase  activity 
compared  to  that  in  NC-transfected  cells.  To  validate  CDK4  as  a  target  of  miR  P-27-5p, 
downregulation of CDK4 at the mRNA and protein level was examined by exon array, real-time PCR, 
and Western blot analyses (Figure 5C,D). CDK4 mRNA and protein in miR P-27-5p–transfected cells 
were decreased compared to NC-transfected cells. These results suggest that CDK4 is the functional Int. J. Mol. Sci. 2012, 13  6362 
 
 
target of miR P-27-5p in T-47D cells and that miR P-27-5p inhibits cell proliferation and causes cell 
cycle arrest via targeting CDK4. 
Figure 5. Down-regulation of CDK4 by miR P-27-5p at the mRNA and protein levels via 
direct targeting of 3′-UTR. (A) The sequences of CDK4 3′-UTR and miR P-27-5p. (B) The 
effect of miR 27-5p on the expression of CDK4 by using luciferase assays. Cells were 
cotransfected with miR P-27-5p duplex or NC with CDK4 3′-UTR. The reporter assays 
shown  in  this  study  were  based  on  data  averaged  from  at  least  three  independent 
transfections. (C) CDK4 mRNA expression was detected by exon array and real-time PCR 
at 48 h after transfection with miR P-27-5p or NC mimetics and normalized against that of 
GADPH. (D) CDK4 protein, (E) Phosphorylated RB1, and RB1 proteins were measured by 
Western blot at 48 h after transfection with miR P-27-5p or NC mimetics. β-actin was used 
as the internal control. All the experiments were conducted in triplicates. 
 
2.5. miR P-27-5p Inhibits RB1 Phosphorylation 
To investigate the association of the miR P-27-5p–induced G1 arrest with RB1 phosphorylation, 
Western  blot  analysis  was  conducted  using  an  RB1  phosphospecific  antibody.  The  results  
showed a decrease in RB1 phosphorylation after transfection with miR P-27-5p (Figure 5E). When 
dephosphorylated, RB1 interacts with E2F transcription factors and prevents transcription of genes 
required  for  progression  through  the  cell  cycle.  By  contrast,  when  phosphorylated  by  cell  
cycle-dependent kinases like CDK2 and CDK4, RB1 no longer interacts with E2F and the cell cycle 
proceeds through the G1/S checkpoint [17]. Loss of cell cycle control is a hallmark of cancer, and 
aberrations in the cyclin-CDK-RB pathway are common in breast cancer [25]. Therefore, targeted 
inhibition of CDK4 activity has a role in the treatment of breast cancer [14,26]. Int. J. Mol. Sci. 2012, 13  6363 
 
 
2.6. Discussion  
Our previous report suggested that miR P-27-5p may be an alternative mature form of miR-802 [6]. 
Our unpublished data indicate that miR P-27-5p is expressed higher in MCF-10A than MCF-7 and 
T47D tumor cells. However, previous study reported endogenous miR-802 was not detected in breast 
cancer  patients  based  on  miRNA  expression  profiles  [27].  On  the  other  hand,  miR-802  was 
investigated in mice by using expression and sequencing studies [28] and Kuhn et al. used miRNA 
expression  profiling,  miRNA  RT-PCR  and  miRNA  in  situ  hybridization  experiments  to  identify  
miR-802 was up-regulated in fetal brain and heart specimens from individuals with Down syndrome 
when comparing with control groups [29]. According to these, miR-802 is expressed in other tissues, 
but not in breast tissues. Thus, the expression levels of miR P-27-5p and miR-802 in breast tissues  
are different. 
Our previous study showed that miR P-27-5p could target Laminin β3 (LAMB3) [6]. LAMB3 has 
been detected in various cancers and affects tumor progression. For example, promoter demethylation 
of LAMB3 causes aberrant LAMB3 expression in gastric cancer and tumor cells stably expressing 
LAMB3 have elevated migration and adhesiveness  [30]. Patients with esophageal  carcinoma have 
worse 5-year survival rates [31]. Additionally, LAMB3 overexpression promotes migration of prostate 
cancer  LNCaP  cells  and  tumor  growth  in  mice  [32].  Thus,  these  results  indicate  that  LAMB3  is 
involved in tumor progression, such as tumor growth and metastasis, and miR P-27-5p may affects 
tumor progression through regulating LAMB3 expression. 
From our exon array, network analysis, and functional enrichment analysis, we predicted that miR 
P-27-5p may have a function in cell cycle and cell proliferation. With cell viability assay and cell cycle 
analysis, we further confirmed that miR P-27-5p induces cancer cell cycle arrest at the G1 phase and 
inhibits cancer cell proliferation. De Guire et al. find that artificial miRNAs reproduce the effects of 
E2Fs inhibition in both normal human fibroblasts and prostate cancer cells, where they inhibit cell 
proliferation  and  induced  cellular  senescence  [33].  Brown  and  Naldini  suggest  utilizing  artificial 
miRNA  target  sites  to  exploit  or  inhibit  endogenous  miRNA  regulation  for  therapeutic  and 
experimental  applications  [34].  Idogawa  et  al.  efficiently  used  a  single  recombinant  adenovirus 
expressing p53 and p21-targeting artificial miRNAs to induce apoptosis in human cancer cells [35]. 
Collectively, artificial miR P-27-5p may represent a novel therapeutic option in breast cancer treatment. 
Previous studies showed that CDK4 regulates progression through the G1/S phase of the cell cycle 
by binding to cyclin D1 to phosphorylate RB1 and releasing E2F transcription factors for progression 
through the cell cycle [36,37]. Decreased cyclin D1 and cyclin D1-CDK4/6 kinase activity reduces the 
invasion  and  migration  potential  of  MDA-MB-231  breast  cancer  cells  [37].  In  this  present  study, 
functional  enrichment  of miR p-27-5p-regulated network showed that  CDK4 is  involved in  many 
biological functions such as posttranslational protein modification, protein amino acid phosphorylation, 
phosphorylation,  cellular protein metabolic process, positive regulation  of cellular process, protein 
modification process, regulation of cell cycle, regulation of cell proliferation, and interphase (Table 1). 
We found that CDK4 and RB1 were hubs within this network and RB1 was one of the interacting 
proteins of CDK4. RB1 is involved in positive regulation of cellular process, regulation of cell cycle, 
regulation of cell proliferation, and interphase. These results are consistent with the reports described 
by Prud’homme et al. [36] and Zhong et al. [37]. Furthermore, we identified their expression levels of Int. J. Mol. Sci. 2012, 13  6364 
 
 
CDK4 and phosphorylated RB1 were reduced in response to miR p-27-5p over-expression. Thus, these 
results indicate that miR p-27-5p may play important roles in cell cycle and proliferation by regulating 
a small subset of genes within its regulated PIN. 
In this study, artificial miR P-27-5p targets the 3′-UTR of CDK4 with mismatches to the central 
region of its targeting site (Figure 5A). Ye et al. designed artificial miRNAs (AmiRs) with mismatches 
targeting the 3′-UTR of viral genome. These small AmiRs combined with pRNA-folate conjugates 
could form a promising system for antiviral drug development [38]. Furthermore, we found that miR 
P-27-5p suppresses the expressions of CDK4, both in mRNA and protein levels (Figure 5C,D), and 
inhibits  RB1  phosphorylation  (Figure  5D),  which  is  one  of  the  CDK4-interacting  proteins  
(Figure 1A). As described previously, CDK4 regulates progression through the G1/S phase of the cell 
cycle by binding to cyclin D1 to phosphorylate RB1 [36,37]. All of the evidence implies that the miR 
P-27-5p–induced cell cycle and inhibited cell proliferation may be through targeting CDK4 and its 
interacting protein, RB1. 
3. Experimental Section 
3.1. Cell Culture and Transfection 
We used one human mammary epithelial (normal) cell line (MCF-10A) and three breast cancer cell 
lines (MCF-7, T-47D) in this study. All the cell lines were purchased from the Bioresource Collection 
and Research Center, Hinchu, Taiwan. Human breast MCF-10A cells were cultured in DMEM/F12 
supplemented  with  5%  horse  serum  and  MCF-7  and  T-47D  cells  were  cultured  in  DMEM 
supplemented  with  10%  FBS  and  100  μg/mL  penicillin/streptomycin  at  37  C  in  a  humidified 
atmosphere of 5% CO2. miR P-27-5p mimics and their corresponding NC were obtained from Ambion 
(Applied Biosystems/Ambion, Austin, TX, USA). Transfection was carried out using Lipofectamine 
2000 (Invitrogen, Inc.) according to the manufacturer’s instructions [6]. 
3.2. Exon Arrays and Data Analysis 
Total  cellular RNA was extracted with  the use of TRIzol  reagent  (Invitrogen), and purity was 
confirmed  by  spectrophotometry  (A260/A280  ratio)  and  capillary  electrophoresis  (Agilent  2100 
Bioanalyzer, Agilent). RNA processing and hybridization onto Affymetrix Human Exon 1.0 ST arrays 
were performed according to the manufacturer’s protocol. Microarray (n = 2 per group) analysis was 
performed by dChip software (dChip 2010.01; Cheng Li Lab of Computational Cancer Genomics: 
Boston, MA, USA, 2010) [39]. Raw data (CEL files) and annotation data were used for computing the 
signal value of exons with Quantile normalization. The exon signal data were later transformed to the 
Affymetrix U133 2.0 PLUS probe set by the export function of dChip software to obtain the gene 
expression value for further analysis. We have submitted the exon array data to the GEO database, and 
the series record is GSE28657. 
3.3. Protein Interaction Network and Functional Enrichment 
Among the significantly differentially expressed genes (p < 0.05), the downregulated genes were 
chosen  due  to  possible  miR  p-27-5p  targets.  The  protein  interaction  networks  with  these Int. J. Mol. Sci. 2012, 13  6365 
 
 
downregulated  genes  were  constructed  based  on  human  PIN  from  the  Human  Protein  Reference 
Database (version 9; Institute of Bioinformatics & Pandey lab: Bangalore, India; Baltimore, MD, USA, 
2010). The possible functions of this network were analyzed by GO functional enrichment, which were 
performed by BiNGO with a threshold of p < 0.001 and a GO level of more than 5 [20]. Enriched 
functions  with  the  CDK4  gene  were  selected  for  further  discussion.  The  method  was  described 
previously [20]. 
3.4. Cell Viability Assay 
Cells (2 ×  10
4 cells/mL) were seeded on 24-well plates. After 24 h, the cells were transfected with 
miR P-27-5p (60 nM). At 24 h, 48 h, or 72 h, MTT (100 μL) was added to each 1 mL of culture 
medium for 4 h of incubation at 37 C and measured at 570 nm by ELISA reader. All experiments 
were performed in triplicates. 
3.5. Cell Cycle Analysis 
Cells (4 ×  10
5) were transfected with miR P-27-5p or a control vector at a final concentration of  
100 nM using Lipofectamine 2000 (Invitrogen, Inc.) for 48 h. After incubation, floating and adherent 
cells  were  harvested.  Cells  were  washed  carefully  with  cold  PBS  at  4  C.  Cell  pellets  were 
resuspended in 100 μL of a binding buffer. Annexin-V FITC (0.2 μg/100 μL) and PI (10 μg/mL) were 
added to the cells and left to incubate in the dark for 15 min at room temperature. All data were 
obtained using flow cytometry with a FACSCanto cytometer (Becton Dickinson, San Jose, CA, USA). 
The  flow  cytometric  analysis  was  performed  using  FCS  Express  (version  4;  DeNovo  software:  
Los Angeles, CA, USA, 2012). All experiments were performed in triplicates. 
3.6. Construction of the CDK4 3′-UTR Report Plasmids and Luciferase Assay 
A CDK4 3′-UTR luciferase reporter was created by inserting full-length human CDK4 3′-UTR into 
the SacI and HindIII sites in the pMIRREPORT luciferase expression vector (Ambion), as described 
before  [6].  Specific  fragments,  including  the  miR  P-27-5p  targeting  site  of  CDK4  3′-UTR,  were 
generated by the primers: 5′-GGG GAG CTC GTT ACC TCA CCG ACG GTA CCT T-3′ (forward) 
and 5′-GGG AAG CTT CTG GTA ATA AAG AAA CAA AAC-3′ (reverse). Clones were selected 
after colony PCR and restriction enzyme digestion. The clones were verified by sequencing (Mission 
Biotech Co., Ltd.). All the restriction enzymes were purchased from New England Biolabs. Reporter 
activity  was  assayed  using  the  Dual-Light  system  (Applied  Biosystems)  and  was  normalized  to  
β-galactosidase activity to control for transfection efficiency variation among different wells according 
to the manufacturer’s instructions. Luminescent signal was quantified by the Spectramax M5 ELISA 
reader (Molecular Devices). All experiments were performed in triplicates. 
3.7. Quantitative Real-Time PCR 
Total  RNA  was  isolated  from  T-47D  cells,  and  first-strand  cDNA  synthesis  was  generated. 
Extracted first-strand cDNAs were analyzed using a BioRad iCycler iQ Real-Time Detection System 
with  the  SYBR  Green  dye  (Molecular  Probes,  Eugene,  OR,  USA).  SYBR  Green  yields  a  strong Int. J. Mol. Sci. 2012, 13  6366 
 
 
fluorescent signal on binding double-stranded DNA, enabling the quantification of gene expression by 
measurement  of  the  intensity  of  the  fluorescent  light.  The  mRNA  expressions  of  CDK4  were 
normalized to RNA content for each sample by using GADPH gene products as internal controls.  
The  relative  expression  levels  were  calculated  as  the  ratio  of  expression  from  miR  P-27-5p  
transfected cancer cells  to the control. All  reactions were run in triplicates. The sequences of the 
primers specific to CDK4 were: forward primer, 5′-CTCTGCGTCCAGCTGCTCCG-3′; and reverse 
primer, 5′-ATCAAGGGAGACCCTCACGC-3′. 
3.8. Western Blot  
The protein (20 μg) was loaded on a 10% SDS-PAGE and subsequently transferred onto PVDF 
membranes (Amersham Biosciences) at 150 V for 1.5 h. The membranes were blocked in 5% nonfat 
milk in PBST containing 0.1% Tween 20, incubated with primary antibody overnight at 4 ° C, and 
followed by incubation with a secondary antibody (a goat antirabbit-conjugated IgG, 1:10000 dilution, 
Upstate). CDK4, phospho-RB1, RB1, and β-actin were purchased from Cell Signaling, Epitomics, 
Epitomics, and Millipore, respectively. After incubation with secondary antibodies, immunoblots were 
visualized with the ECL detection kit (Amersham Biosciences) and exposed to x-ray film. The protein 
bands  were  quantified  using  ImageMaster  software  version  6.0  (Amersham  Pharmacia  Biotech, 
Geneva, Switzerland, 2005), and the data were normalized to β-actin. 
3.9. Statistical Analysis  
Statistical  analysis  was  performed  using  Microsoft  Office  Excel  2007  (Microsoft  Corporation: 
Redmond, WA, USA, 2007). Student’s t test and P-values were tested for multiple comparisons by 
controlling the false discovery rate. Changes were considered significant if the false discovery rate was 
less than 0.05. 
4. Conclusions 
Our  results  reveal  that  miR  P-27-5p  targets  and  negatively  regulates  CDK4,  which  in  turn 
suppresses  RB1  phosphorylation,  thereby  preventing  the  progression  of  cancer  cell  cycle  and 
promoting G1 arrest. As a consequence, cancer cell proliferation is inhibited. Thus, on the therapeutic 
side, artificial miR P-27-5p has the potential for the application in the treatment of breast cancer. 
miRNA can affect many downstream targets, which in turn form a complicated network. Therefore, 
there is considerable potential for the miRNA-regulated network to be a novel therapeutic target. The 
therapeutic strategy could be used for cancer as well as the other diseases such as neurological and 
cardiovascular disorders. RNA interference and miRNA oligonucleotides have clinical potential. In the 
future, using the miR P-27-5p-regulated network as a novel therapeutic target, especially responsible 
for G1 arrest, may help reduce off-target effects and alleviate the risk of side effects. 
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